| Alan E Lichtin, MD | |
|
9500 Euclid Ave, Cleveland, OH 44195-0001 | |
| (800) 223-2273 | |
| Not Available |
| Full Name | Alan E Lichtin |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 44 Years |
| Location | 9500 Euclid Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366406456 | NPI | - | NPPES |
| 0715828 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 35048291L (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Cleveland Clinic Avon Hospital | Avon, OH | Hospital |
| Hillcrest Hospital | Mayfield heights, OH | Hospital |
| Akron General Medical Center | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
Getting new medical treatments from the lab benchtop to patients' bedsides can be harder and more expensive than putting a lander on Mars. But it doesn't have to be, says Tiffany Wilson, who heads a nonprofit organization that guides new medical solutions from the lab bench to the bedside.
New research from Queen Mary University of London has found youth, wealth, and being in full-time education to be risk factors associated with violent radicalisation. Contrary to popular views - religious practice, health and social inequalities, discrimination, and political engagement showed no links.
› Verified 3 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
Getting new medical treatments from the lab benchtop to patients' bedsides can be harder and more expensive than putting a lander on Mars. But it doesn't have to be, says Tiffany Wilson, who heads a nonprofit organization that guides new medical solutions from the lab bench to the bedside.
New research from Queen Mary University of London has found youth, wealth, and being in full-time education to be risk factors associated with violent radicalisation. Contrary to popular views - religious practice, health and social inequalities, discrimination, and political engagement showed no links.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alan E Lichtin, MD 6000 W Creek Rd, Suite 10, Independence, OH 44131-2139 Ph: (800) 223-2273 | Alan E Lichtin, MD 9500 Euclid Ave, Cleveland, OH 44195-0001 Ph: (800) 223-2273 |
News Archive
AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
Getting new medical treatments from the lab benchtop to patients' bedsides can be harder and more expensive than putting a lander on Mars. But it doesn't have to be, says Tiffany Wilson, who heads a nonprofit organization that guides new medical solutions from the lab bench to the bedside.
New research from Queen Mary University of London has found youth, wealth, and being in full-time education to be risk factors associated with violent radicalisation. Contrary to popular views - religious practice, health and social inequalities, discrimination, and political engagement showed no links.
› Verified 3 days ago
Amir Razavi, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Dr. Francois Fadell, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 18200 Lorain Ave, Moll Cancer Center At Fairview- Respiratory Institute, Cleveland, OH 44111 Phone: 216-444-6503 | |
Sana Hasan, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 Phone: 330-721-5700 | |
Catherine Frakes Vozzo, DO Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-4444 Fax: 216-445-6290 | |
Tarek Ashour, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave # Q7, Cleveland, OH 44195 Phone: 216-444-5040 | |
Mrs. Efewongbe Benedicta Oleghe, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2351 E 22nd Street, St Vincent's Charity Medical Center, Cleveland, OH 44115 Phone: 216-363-2725 | |
Dr. Toufik Z. Madhun, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave Dept Of, Cleveland, OH 44106 Phone: 216-844-1000 |